AARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class Action

Aardvark Therapeutics faces a securities class action alleging it overstated the safety, regulatory and commercial prospects of lead drug candidate ARD-101. Following a February 2026 Phase 3 HERO trial pause over cardiac observations and a May 2026 FDA full clinical hold covering both Phase 3 studies, AARD fell from its $16.00 February 2025 offering price to $4.57, a 71.4% decline. The litigation covers investors who purchased between February 13, 2025 and May 14, 2026, with an October 13, 2026 lead-plaintiff deadline.

Analysis

The litigation notice is not itself a new fundamental catalyst; the investable issue remains whether AARD can produce a credible FDA remediation path for the cardiac signal. With a single lead asset effectively frozen, the equity is a financing-duration instrument: each quarter without hold resolution increases cash-burn dilution risk and lowers the probability-weighted value of any eventual pivotal program. The original safety narrative has also been impaired, meaning even a restart is unlikely to restore the prior commercial or valuation framework without detailed exposure-response and cardiac-monitoring data.

Near term, expect litigation-driven retail attention but limited incremental institutional repricing absent an FDA communication, cash update, or management disclosure on the hold requirements. The October lead-plaintiff deadline has no bearing on clinical value; securities claims typically create defense costs and discovery risk over years, but are subordinate to the regulatory timeline. The more material second-order risk is that potential strategic partners will demand materially worse economics—or defer engagement entirely—until systemic exposure and cardiac risk are independently de-risked.

Consensus may overemphasize the headline share-price collapse as creating automatic optionality. A full hold after a Phase 3 pause can be recoverable, but the relevant valuation question is not the pre-hold price; it is cash runway through remediation, the FDA's required nonclinical/clinical package, and whether the therapeutic window survives any dose restriction. AARD becomes actionable only when the company quantifies those items; absent that disclosure, downside is governed by financing terms rather than the lawsuit.

Key Decisions for Investors

• Avoid initiating a directional long on the litigation release. Reassess only after AARD discloses the FDA hold protocol, estimated restart timing, and cash runway; a restart without a dose-limiting commercial impact would be the first genuine 1-3 month catalyst.
• For existing long exposure, treat the next cash-runway update as the primary risk event. Reduce exposure if projected liquidity does not extend at least 12 months beyond the stated remediation timeline, since a discounted equity raise could dominate any hold-resolution upside.
• Do not short solely on this notice after the major clinical repricing; borrow availability and a low absolute share price can make risk/reward asymmetric. A short becomes more attractive only following a liquidity-driven rebound unsupported by FDA clarification, with a stop on documented hold resolution or a funded strategic transaction.
• Monitor FDA correspondence, revised trial design, pharmacokinetic exposure data, and cardiac-event detail rather than court milestones. Falsify the bearish operating thesis if management provides a defined, funded remediation plan and FDA clearance to resume both studies without a materially reduced target dose.